chevron_leftBack
As of 13 June 2026, Serina Therapeutics, Inc. has a market cap of $22.53M USD, ranking #36257 globally and #4937 in the United States.
It ranks #8283 in the Industrials sector, and #1028 in the Specialty Business Services industry.
Key Stats
Market Cap
$22.53MUSD
Enterprise Value
$23.05MUSD
Revenue (TTM)
$130.0KUSD
EBITDA (TTM)
-$23.95MUSD
Net Income (TTM)
-$19.44MUSD
PS Ratio
175.2
Company Profile
Country (HQ)
Sector
Industrials
Industry
Specialty Business Services
CEO
Steven Ledger
open_in_new
Employees
13
Founded
2017
IPO
29 Nov 2018
Website
serinatherapeutics.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -1.1% | -12% | -21% | -34% | -65% | -69% |
News
Loading...
SER Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
SER
Serina Therapeutics Inc
ISIN: US81751A1088
Shares Out.:
Shares Outstanding:
14.998M1
Shares Float:
10.635M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
1.83 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Serina Therapeutics, Inc.
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson’s disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson’s and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: CTAS
|
$69.6B
309K%
|
36.8
|
|
NASDAQ: PYPL
|
$45.83B
203K%
|
9.4
|
|
NYSE: XYZ
|
$41.37B
184K%
|
33.1
|
|
NASDAQ: FISV
|
$33.06B
147K%
|
9.8
|
|
NYSE: ROL
|
$26.64B
118K%
|
51.1
|
|
NYSE: CPAY
|
$20.3B
90K%
|
20.7
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: SHOP
|
$158.14B
702K%
|
129.8
|
|
STO: VSURE
|
$132.68B
589K%
114.8B EUR
|
-
|
|
LSE: REL
|
$63.78B
283K%
47.6B GBP
|
23.9
|
|
|
T
NEO: TRI
|
$41.8B
185K%
56.91B CAD
|
-
|
|
AMS: UMG
|
$41.12B
182K%
35.58B EUR
|
23.4
|
|
AMS: ADYEN
|
$34.79B
154K%
30.1B EUR
|
28.4
|
chevron_leftBack